Key statistics
As of last trade Ascletis Pharma Inc (2VJ:DUS) traded at 1.72, -13.57% below its 52-week high of 1.99, set on Aug 18, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.68 |
|---|---|
| High | 1.72 |
| Low | 1.68 |
| Bid | 1.72 |
| Offer | 1.85 |
| Previous close | 1.81 |
| Average volume | 277.78 |
|---|---|
| Shares outstanding | 991.87m |
| Free float | 300.08m |
| P/E (TTM) | -- |
| Market cap | 17.00bn HKD |
| EPS (TTM) | -0.2984 HKD |
Data delayed at least 15 minutes, as of Feb 11 2026 08:30 GMT.
More ▼
Press releases
- Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
- Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
- Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
- Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
- Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
- Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
More ▼
